Tradr 2X Long SRPT Daily ETF

SharonAI Holdings Inc.

Rackspace Tech

Sensei Biotherapeutics

Cardio Diagnostics

Moolec Science SA

RenX Enterprises

ImmunityBio

Nuveen Real Asset Income and Growth Fund

Neo-Concept

TMD Energy

IBBQ

SBIO

ARKG

SRPU

SRPT

Sarepta Therapeutics, Inc. will announce its fourth quarter and full-year 2025 financial results on February 25, 2026, after the Nasdaq closes. A conference call will follow at 4:30 p.m. E.T. to discuss the results, which will be webcast live on the company's website. Sarepta focuses on precision genetic medicine for rare diseases, particularly Duchenne muscular dystrophy, and maintains an active investor relations section on its website for updates.

Reuters

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

iShares Biotechnology ETF

iShares US Pharma

Ark Genomic Revolution ETF

VG Health

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

VanEck Biotech ETF

Health Care Select Sector SPDR

Sarepta Therap

Proshares Ultra Nasdaq Biotech

Sarepta Therapeutics To Announce Fourth Quarter And Full-Year 2025 Financial Results

Sarepta Therapeutics Inc :SAREPTA THERAPEUTICS ANNOUNCES APPROVAL OF CLINICAL TRIAL APPLICATION FOR SRP-1005, ITS INVESTIGATIONAL TREATMENT FOR HUNTINGTON’S DISEASESAREPTA THERAPEUTICS INC - FIRST-IN-HUMAN CLINICAL STUDY OF SRP-1005, KNOWN AS INSIGHTT, IS EXPECTED TO BEGIN IN Q2 OF 2026SAREPTA THERAPEUTICS INC: FIRST-IN-HUMAN CLINICAL STUDY OF SRP-1005, KNOWN AS INSIGHTT, IS EXPECTED TO BEGIN IN Q2 OF 2026

Sarepta Therapeutics Announces Clinical Trial Application Approval For SRP-1005 In Huntington’s Disease

Sarepta Therapeutics (NASDAQ:SRPT) announced three-year results from its EMBARK Phase 3 trial for ELEVIDYS, a gene therapy for Duchenne muscular dystrophy (DMD). The data showed significant disease-modifying effects, with treated patients demonstrating a 4.39-point improvement in NSAA and a 6-second advantage in time to arise compared to external controls. No new safety concerns were reported. Analysts remain optimistic, projecting a 179% upside despite challenges ahead for the company.

Market Beat

Proshares UltraShort Nasdaq Biotech

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags

COGT

IBRN

LABD

Health care stocks saw gains late Monday, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF rising 0.5%. Biogen's shares increased 1% following FDA review news for Leqembi. Sarepta Therapeutics surged 7.2% on positive trial results for Elevidys, while Cogent Biosciences rose 3.2% after receiving breakthrough therapy designation. Conversely, Merck's shares fell 0.7% after dropping its bid for Revolution Medicines, which plummeted nearly 17%.

fidelity

Cogent Biosciences

iShares Neuroscience And Healthcare ETF

iShares US Medical Devices

SPDR S&P Health

Biogen

SPDR S&P Health Equip

Direxion S&P Biotech Bear 3X

Sector Update: Health Care Stocks Advance Late Afternoon

U.S. stocks rose on Monday, with the Dow Jones gaining over 100 points. Sarepta Therapeutics shares surged 9.8% after positive results from its Phase 3 study of Elevidys for Duchenne muscular dystrophy. Lands' End jumped 38.8% following a joint venture announcement. Other notable gainers included Alpha Technology Group (+26.8%), Rich Sparkle Holdings (+22%), and TRX Gold (+18%). Precious metals stocks rose amid safe-haven demand due to geopolitical concerns. USA Rare Earth climbed 14.3% after a funding announcement with the U.S. government. CoreWeave gained 9.5% after expanding its collaboration with Nvidia.

benzinga_article

Lands End

USA Rare Earth - CW300313

TRX Gold

Guggenheim DJIA Ave Div

USA Rare Earth

Dow Jones U.S. Index

Coreweave

Rich Sparkle

Pro UltrPro Dow30

iShares Dow Jones US

Dow Jones Industrial Average

SPDR Djia

Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday

Sarepta Therapeutics Inc. announced positive three-year results from its Phase 3 EMBARK study of Elevidys for Duchenne muscular dystrophy. Patients treated with Elevidys showed significant improvements in motor function, with a 73% slowing of disease progression compared to a control group. The drug is the only approved gene therapy for Duchenne and has been administered to over 1,200 patients. Sarepta reported fourth-quarter product revenue of $369.6 million and full-year revenue of $1.86 billion for 2025. Shares rose 5.06% to $22.20 in premarket trading.

Sarepta Says Elevidys Slows Duchenne Progression After Three Years

Sarepta Therapeutics shares are trading higher after the company announced topline three-year functional results from Part 1-treated patients in EMBARK study.

Sarepta Therapeutics' gene therapy, Elevidys, has shown sustained benefits in slowing disease progression in patients with Duchenne muscular dystrophy, according to three-year data from a late-stage study. The therapy improved patients' ability to perform physical activities and demonstrated a 73% reduction in disease progression compared to untreated controls. Despite previous safety concerns, the positive long-term results may help restore confidence in Elevidys, which is crucial for the company's sales amid scrutiny over its effectiveness.

Sarepta's Duchenne gene therapy slows disease progression, three-year data shows

Genethon, a non-profit gene therapy R&D organization, is advancing gene therapies for rare genetic diseases, including Duchenne muscular dystrophy (DMD) and Pompe disease. The organization has entered a licensing deal with AskBio for a proprietary technology and is conducting pivotal clinical trials for its micro-dystrophin gene therapy (GNT0004) for DMD. CEO Frederic Revah highlights the dedication of Genethon's 240 scientists in developing innovative treatments. The latest newsletter also features updates on clinical trials and research discoveries related to gene therapy for DMD.

MorningStar

Genethon Advances Groundbreaking Gene Therapies for Patients with Rare Genetic Diseases

Sarepta Therapeuticsshares rose 6.4% to $22.49 in premarket trading. The company announced it will present three-year results from its EMBARK trial of Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), on January 26 at 8:30 a.m. ET. The trial tested Elevidys against a placebo in boys aged 4 to 7 who had not lost the ability to walk due to DMD. Shares previously fell approximately 82% in 2025.

BUZZ-Sarepta to release 3-year data for muscle dystrophy gene therapy; shares rise

U.S. stock futures fell as major indices declined ahead of earnings reports from companies like UnitedHealth and Microsoft. The Dow Jones dropped 0.12%, S&P 500 down 0.24%, Nasdaq 100 down 0.44%, and Russell 2000 down 0.29%. The 10-year Treasury bond yield is at 4.21%. Notable stocks include Baker Hughes up 3.74% and Sarepta Therapeutics up 6.72%. The Fed is expected to keep interest rates steady, with a 97.2% likelihood of no change in January.

Unusual Whales

YieldMax MSFT Option Income Strategy ETF

T-Rex 2X Long Microsoft Daily Target ETF

VG S&P 500

Invesco QQQ Trust

GraniteShares 2x Long MSFT Daily ETF

Ps S&P Low Vol

VG Mga Cap 300 Grw

Direxion Daily MSFT Bull 2X Shares

iShares Core S&P 500

Baker Hughes

S&P 500

NASDAQ-100

SPDR S&P 500

U.S. stock futures fell as investors prepare for mega-cap earnings. Market indices down, with 10-year Treasury bond at 4.21%. Notable stocks include BKR up 3.74% and SRPT up 6.72%. Fed likely to keep interest rates steady. Dow Jones -0.12%, S&P 500 -0.24%, Nasdaq 100 -0.44%, Russell 2000 -0.29%. SPY down 0.22% to $687.69, QQQ declined 0.43% to $620.04.

Sarepta Therapeutics Inc. will present three-year topline results from the EMBARK Phase 3 study of ELEVIDYS in Duchenne muscular dystrophy on January 26, 2026. The presentation will be available via a webcast and conference call on the company's investor relations website, with a replay accessible for one year.

Sarepta Therapeutics to Present 3-Year Topline Results from EMBARK Phase 3 Study of ELEVIDYS in Duchenne Muscular Dystrophy

AEON

Biotech stocks experienced significant movements in after-hours trading, led by Sarepta Therapeutics (SRPT), which surged 9.65% to $23.17 ahead of key trial data. Other notable gainers included Fractyl Health (GUTS) up 7.66%, Greenwich LifeSciences (GLSI) rising 2.08% after FDA approval of GP2 vials, and Anebulo Pharmaceuticals (ANEB) increasing 8.41%. Trevi Therapeutics (TRVI) gained 3.40% following positive trial results published in JAMA. AEON Biopharma (AEON) edged up 1.80% after securing FDA meeting and shareholder approval for financing transactions.

rttnews

AEON Biopharma, Inc.

Anebulo Pharmaceuticals

Greenwich Lifesciences

Trevi Therapeutics

Fractyl Health

After-Hours Gainers: Biotech Stocks In Focus

Sarepta jumps on upcoming release of 3-year Elevidys data

businessinsider

Sarepta jumps on upcoming release of 3-year Elevidys data

Sarepta Therapeutics Inc :SAREPTA THERAPEUTICS TO REPORT 3-YEAR TOPLINE DATA FROM EMBARK STUDY OF ELEVIDYS GENE THERAPY IN AMBULATORY INDIVIDUALS WITH DUCHENNE MUSCULAR DYSTROPHY

Sarepta Therapeutics To Report 3-Year Topline Data From Embark Study Of Elevidys Gene Therapy

Tradr 2X Long SRPT Daily ETF(SRPU.US)

Sarepta Therapeutics To Announce Fourth Quarter And Full-Year 2025 Financial Results

Sarepta Therapeutics Announces Clinical Trial Application Approval For SRP-1005 In Huntington’s Disease

Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags

Sector Update: Health Care Stocks Advance Late Afternoon

Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday